New combo therapy aims to stall lung cancer

NCT ID NCT03519971

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage III lung cancer that cannot be removed by surgery. About 328 participants will receive either durvalumab or a placebo alongside their chemo and radiation. The main goal is to see if the combination delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (an immunotherapy drug) given with chemotherapy and radiation
What this could lead to: If it works, this could offer a new treatment option that helps control stage III lung cancer for longer without the cancer growing.
What could go wrong: This is still being tested, and results may not show a clear benefit. Immunotherapy can cause side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site

Barretos, 14784-400, Brazil
Research Site

Curitiba, 81520-060, Brazil
Research Site

Florianópolis, 88034-000, Brazil
Research Site

Fortaleza, 60336-045, Brazil
Research Site

Porto Alegre, 90035-003, Brazil
Research Site

Porto Alegre, 90610-000, Brazil
Research Site

Porto Alegre, 91350-200, Brazil
Research Site

Ribeirão Preto, 14021-636, Brazil
Research Site

Ribeirão Preto, 14048900, Brazil
Research Site

São José do Rio Preto, 15090-000, Brazil
Research Site

São Paulo, 01246-000, Brazil
Research Site

Brno, 656 53, Czechia
Research Site

Ostrava, 703 00, Czechia
Research Site

Prague, 128 08, Czechia
Research Site

Budapest, 1083, Hungary
Research Site

Budapest, 1121, Hungary
Research Site

Győr, 9024, Hungary
Research Site

Gyula, 5700, Hungary
Research Site

Törökbálint, 2045, Hungary
Research Site

Bangalore, 560068, India
Research Site

Chennai, 600035, India
Research Site

Gurgaon, 122001, India
Research Site

Karamsad, 388325, India
Research Site

Mumbai, 400053, India
Research Site

Nashik, 422005, India
Research Site

New Delhi, 110063, India
Research Site

Vadodara, 390007, India
Research Site

Bunkyō City, 113-8603, Japan
Research Site

Fukuoka, 812-8582, Japan
Research Site

Kōtoku, 135-8550, Japan
Research Site

Kyoto, 606-8507, Japan
Research Site

Nagoya, 464-8681, Japan
Research Site

Sayama, 589-8511, Japan
Research Site

Sendai, 980-0873, Japan
Research Site

Yokohama, 241-8515, Japan
Research Site

Aguascalientes, 20230, Mexico
Research Site

Guadalajara, 44280, Mexico
Research Site

Mexico City, 0 3100, Mexico
Research Site

Mérida, 97134, Mexico
Research Site

México, 04700, Mexico
Research Site

Orizaba, 94300, Mexico
Research Site

La Libertad, 13013, Peru
Research Site

Lima, 15033, Peru
Research Site

Lima, L27, Peru
Research Site

Lima, LIMA 27, Peru
Research Site

Lima, LIMA 34, Peru
Research Site

Lima, LIMA 41, Peru
Research Site

Cebu City, 6000, Philippines
Research Site

City of Taguig, 1634, Philippines
Research Site

Iloilo City, 5000, Philippines
Research Site

Makati, 1229, Philippines
Research Site

Manila, 1015, Philippines
Research Site

Quezon City, Philippines
Research Site

Bydgoszcz, 85-796, Poland
Research Site

Elblag, 02-300, Poland
Research Site

Gdansk, 80-952, Poland
Research Site

Olsztyn, 10-228, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Arkhangelsk, 163045, Russia
Research Site

Chelyabinsk, 454087, Russia
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 115533, Russia
Research Site

Moscow, 125367, Russia
Research Site

Omsk, 644013, Russia
Research Site

Rostov-on-Don, 344037, Russia
Research Site

Saint Petersburg, 197758, Russia
Research Site

Busan, 48108, South Korea
Research Site

Chungcheongbuk-do, 28644, South Korea
Research Site

Gyeongsangnam-do, 52727, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 6351, South Korea
Research Site

Bangkok, 10330, Thailand
Research Site

Bangkok, 10400, Thailand
Research Site

Hat Yai, 90110, Thailand
Research Site

Khon Kaen, 40002, Thailand
Research Site

Mueang, 50200, Thailand
Research Site

Ankara, 06230, Turkey (Türkiye)
Research Site

Ankara, Turkey (Türkiye)
Research Site

Antalya, 07059, Turkey (Türkiye)
Research Site

Diyarbakır, 21280, Turkey (Türkiye)
Research Site

Istanbul, 34030, Turkey (Türkiye)
Research Site

Izmir, 35100, Turkey (Türkiye)
Research Site

Hanoi, 100000, Vietnam
Research Site

Hanoi, 10000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.